GoodRx (GDRX) Stock Price, News & Analysis

Company Overview

GoodRx Holdings, Inc. operates a digital healthcare platform that helps consumers find and access lower prices for prescription medications. Through its website and mobile applications, GoodRx allows users to compare prices at participating pharmacies, obtain prescription discount coupons and identify potential savings on commonly prescribed drugs. The company’s services are generally available at pharmacies across the United States.

GoodRx also offers GoodRx Gold, a membership program that provides additional discounts on eligible prescriptions, as well as healthcare-related content and tools designed to help consumers understand medications and treatment options. Its platform connects consumers with pharmacies, healthcare providers and pharmaceutical companies, supporting prescription savings, medication information and other consumer healthcare services.

The company was founded in 2011 by Trevor Bezdek, Doug Hirsch and Scott Marlette. GoodRx became a publicly traded company on the Nasdaq under the symbol GDRX in 2020. Its business is primarily focused on the U.S. healthcare market and is intended to complement, rather than replace, traditional health insurance by helping consumers compare out-of-pocket prescription costs.

Key Stats

• Today's Range: $3.48 to $3.60
• 50-Day Range: $3.23 to $3.72
• 52-Week Range: $1.77 to $3.99
• Volume: 891,950 shs
• Average Volume: 978,739 shs
• Market Capitalization: $1.22 billion
• P/E Ratio: 89.02
• Dividend Yield: N/A
• Price Target: $4.23
• Consensus Rating: Hold

GoodRx Stock Analysis - MarketRank™

GoodRx scored higher than 91% of companies evaluated by MarketBeat, and ranked 58th out of 907 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Hold

Consensus Rating

GoodRx has received a consensus rating of Hold. The company's average rating score is 2.08, and is based on no strong buy ratings, 4 buy ratings, 6 hold ratings, and 3 sell ratings.

Upside Potential

GoodRx has a consensus price target of $4.23, representing about 18.7% upside from its current price of $3.56.

Amount of Analyst Coverage

GoodRx has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 25.00%

Earnings Growth

Earnings for GoodRx are expected to grow by 25.00% in the coming year, from $0.16 to $0.20 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of GoodRx is 23.60, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 26.91.

Price to Earnings Ratio vs. Sector

The P/E ratio of GoodRx is 23.60, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 36.55.

Price to Earnings Growth Ratio

GoodRx has a PEG Ratio of 1.76. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

GoodRx has a P/B Ratio of 1.97. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.14% of the float of GoodRx has been sold short.

Short Interest Ratio / Days to Cover

GoodRx has a short interest ratio ("days to cover") of 4.22.

Change versus previous month

Short interest in GoodRx has recently decreased by 11.56%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

GoodRx does not currently pay a dividend.

Dividend Growth

GoodRx does not have a long track record of dividend growth.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 1.40

News Sentiment

GoodRx has a news sentiment score of 1.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for GoodRx this week, compared to 3 articles on an average week.

Search Interest

Only 2 people have searched for GDRX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

2 people have added GoodRx to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.6 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, GoodRx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $9,673,207.00 in company stock.

Percentage Held by Insiders

5.87% of the stock of GoodRx is held by insiders.

Percentage Held by Institutions

63.77% of the stock of GoodRx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/05/2026
• Today: 10/26/2026
• Next Earnings (Estimated): 11/03/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Technology
• Sub-Industry: Healthcare Technology
• Current Symbol: NASDAQ:GDRX
• CIK: 1809519
• Web: www.goodrx.com
• Phone: 855-268-2822
• Fax: N/A
• Employees: 697
• Year Founded: 2011

Price Target and Rating

• Average Price Target for GoodRx: $4.23
• High Price Target: $5.00
• Low Price Target: $2.75
• Potential Upside/Downside: +18.7%
• Consensus Rating: Hold
• Rating Score (0-4): 2.08
• Research Coverage: 13 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.04
• Trailing P/E Ratio: 89.02
• Forward P/E Ratio: 22.25
• P/E Growth: 1.76
• Net Income: $30.44 million
• Net Margins: 2.07%
• Pretax Margin: 5.27%
• Return on Equity: 7.22%
• Return on Assets: 2.53%

Debt

• Debt-to-Equity Ratio: 0.74
• Current Ratio: 1.38
• Quick Ratio: 1.38

Sales & Book Value

• Annual Sales: $796.85 million
• Price / Sales: 1.53
• Cash Flow: $0.40 per share
• Price / Cash Flow: 8.85
• Book Value: $1.81 per share
• Price / Book: 1.97

Miscellaneous

• Outstanding Shares: 342,570,000
• Free Float: 322,465,000
• Market Cap: $1.22 billion
• Optionable: Optionable
• Beta: 1.69